No Data
No Data
No Data
No Data
No Data
North China Pharmaceutical Company.Ltd (SHSE:600812) Strong Profits May Be Masking Some Underlying Issues
North China Pharmaceutical Company.Ltd (SHSE:600812) just released a solid earnings report, and the stock displayed some strength. Despite this, our analysis suggests that there are some factors weak
Simply Wall StMay 3 06:29
Express News | The National Health Insurance Administration revealed 25 “particularly serious” and “seriously” untrustworthy pharmaceutical companies, including North China Pharmaceutical
BreakingsApr 30 08:22
Should We Be Cautious About North China Pharmaceutical Company.Ltd's (SHSE:600812) ROE Of 1.2%?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business.
Simply Wall StApr 27 10:03
Huabei Pharmaceutical (600812.SH) reported first-quarter results, with net profit of 18.1524 million yuan, an increase of 234.89% over the previous year
Huabei Pharmaceutical (600812.SH) released its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
Zhitong FinanceApr 25 18:26
About 84.925,600 restricted shares of Huabei Pharmaceutical (600812.SH) will be listed and circulated on April 9
Huabei Pharmaceutical (600812.SH) issued an announcement. The number of shares listed and in circulation for which restrictions have been lifted is about 8,492...
Zhitong FinanceApr 1 17:05
Express News | Huabei Pharmaceutical: Net profit of 4.893 million yuan in 2023, R&D investment increased by more than 90% year-on-year
BreakingsApr 1 12:39
No Data
No Data